What to Ask About Herpes

The most common signs are sores orulcers on the genitals, as well as general pain or itching around the groin. These symptoms can flare up for a few days and then disappear, with the first outbreak often being the most severe. As many as 80 percent who have herpes, however, do not notice anything wrong, or think their symptoms are an unrelated problem. A blood test can confirm if you have one of the two viruses that cause genital herpes.

Herpes Simplex - Drug Pipeline Analysis and Market Forecasts to 2016

The global herpes simplex therapeutics market was worth approximately $2.9 billion in 2009. In 2001 the market was valued at approximately $1 billion and it grew at an approximate Compound Annual Growth Rate (CAGR) of 14% from 2001 to 2009. The global Herpes Simplex therapeutics market is expected to reach $6 billion by 2016, growing at a CAGR of 11.1%. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently, the therapeutic regimen for herpes simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC (Over The Counter) products such as Abreva and Aviralex. This market is a significantly genericized market, with many brands across the seven geographies covered. Tablet prices range between $1 and $3 depending on the brand. The average annual cost of therapy for herpes simplex therapeutics ranges between $725 and $2,050 based on the treatment regimen (reduction or suppression therapy).